Thursday, 3 March 2016
AstraZeneca today announced that its AZ&MeTM Prescription Savings Programs provided more than $617 million in savings on medicines to patients in the United States in 2015. The programs supported nearly 286,000 patients last year.
“As the healthcare market continues to change, patients sometimes need support in paying for their prescription medicines,” said Diane Sullivan, Vice President, Market Access and Patient Strategies. “We are proud of our long-standing commitment to making great medicines – and helping patients access them.”
Since 2010, AstraZeneca has provided more than $5.5 billion in savings to patients in its savings programs. The programs are designed to help qualifying people without insurance, those enrolled in Medicare Part D, those who receive their medications through participating healthcare facilities and those who recently faced a financial challenge – such as loss of a job.
- Individuals without Prescription Drug Coverage: AstraZeneca provides free medicines to qualifying individuals with an annual income at or below $35,000 and families of four with an annual household income at or below $70,000. Certain specialty and oncology medicines are provided free to qualifying individuals with an annual household income up to $100,000 regardless of family size.
- Part D Beneficiaries: AstraZeneca provides free medicines to qualifying Medicare Part D beneficiaries with an annual income at or below $35,000 and couples with an annual household income at or below $48,000.
- Healthcare Facilities: AstraZeneca provides free medicines to qualifying non-profit organizations, such as disproportionate share hospitals, community health centers and community free clinics. This program helps provide medicines to qualifying patients at the time and place of treatment.
AstraZeneca first launched its prescription savings program more than 35 years ago, helping millions of patients afford the medicines they need. The company also participates in multi-manufacturer programs like the Partnership for Prescription Assistance and support other organizations with the same goal—increasing access to medicines as well as healthcare.
NOTES TO EDITORS
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology – as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please www.astrazeneca-us.com.
|Michele Meixell||+1 302 885 2677|
|Abigail Bozarth||+1 302 885 2677|
For more information about AstraZeneca in the United States, or our AZ&Me Prescription Savings Programs, please visit www.astrazeneca-us.com or call 1-800-AZandMe (292-6363).
AZ&Me is a trademark of the AstraZeneca group of companies. ©2015 AstraZeneca. All rights reserved.